Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > How high can this go Walter $20 maybe. Could be big

<< Previous

Bullboard Posts

Next >>

Comment by WalterTheDawgon Apr 18, 2022 4:00pm

134 Views

Post# 34611162

RE:How high can this go Walter $20 maybe. Could be big

I have no real thoughts on long term price. Stem cell adoption by the FDA is still in it's infancy but there are a few approved in Canada. I do have near term targets that are over double todays SP based on how the company will be valued after good to great results from their phase 2 clinical trial and they are very conservative. I'll leave the big dreams to big dreamers.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"